Gedeon Richter Gearing Up For Denosumab And Tocilizumab
As Terrosa Sales On Course For Target
Executive Summary
Hungary’s Gedeon Richter is continuing efforts to bring multiple biosimilars to market, while reaping the benefits of the biosimilar to Eli Lilly’s Forsteo (teriparatide) in the EU and Japan. Management discussed Richter’s achievements on the company’s first-half earnings call, while also commenting on how markets have reacted to the COVID-19 pandemic.
You may also be interested in...
Fresenius Kabi Gets Ready To Launch Europe’s First Tocilizumab Rival
Fresenius Kabi has celebrated the approval of Europe’s first tocilizumab biosimilar. The rival to RoActemra is expected to be launched later this year under a settlement agreement with originator Genentech.
Dr Reddy’s Sees Tocilizumab Clear Phase I
Dr Reddy’s says it is moving its biosimilar tocilizumab candidate into Phase III trials after successfully completing a Phase I study for the proposed rival to Actemra/RoActemra.
Richter’s Biosimilar Costs ‘Took Up A Lot Of Resources Last Year’
Hungary’s Gedeon Richter is continuing to divert the greatest proportion of its R&D cash to biosimilars. Management updated on its pipeline and broader group prospects amid Russia’s military invasion of Ukraine.